Interv Akut Kardiol. 2014;13(2):73-75

Novel oral anticoagulants and acute myocardial infarction

Ivo Varvařovský
Kardiologické centrum Agel, Pardubice

Novel oral anticoagulants (NOAC) are considered better then warfarin for prevention of ischemic stroke and systemic embolization in

nonvalvular atrial fibrillation. Direct thrombin inhibitors and factor Xa inhibitors have a different influence on the risk of myocardial

infarction. Considering the risk of myocardial infarction should be part of the decision-making process for long-term NOAC therapy.

Keywords: novel oral anticoagulants (NOAC), warfarin, acute myocardial infarction

Published: May 15, 2014  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Varvařovský I. Novel oral anticoagulants and acute myocardial infarction. Interv Akut Kardiol. 2014;13(2):73-75.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Hart RG, Pearce LA, Aquilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med 2007; 146: 857-867. Go to original source... Go to PubMed...
    2. Connolly SJ, Ezekowitz MD, Yusuf S. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009; 361: 1139-1151. Go to original source... Go to PubMed...
    3. Patel MR, Mahaffey KW, Garg J. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011; 365: 883-8891. Go to original source... Go to PubMed...
    4. Granger CB, Alexander JH, McMurray JJ. Apixaban in patients with atrial fibrillation. N Engl J Med 2011; 365: 981-992. Go to original source... Go to PubMed...
    5. Lip GYH, Lane DA. Does warfarin for stroke thromboprophylaxis protect against MI in atrial fibrillation patients? Am J Med 2010; 123: 785-789. Go to original source... Go to PubMed...
    6. Smith P, Arnesen H, Holme I. The effect of warfarin on mortality and reinfarction after myocardial infarction. N Engl J Med 1990; 323: 147-1452. Go to original source... Go to PubMed...
    7. Hurlen M, Abdelnoor M, Smith P. Warfarin, aspirin, or both after myocardial infarction. N Engl J Med 2002; 347: 969-974. Go to original source... Go to PubMed...
    8. Rothberg MB, Celestin C, Fiore LD. Warfarin plus aspirin after myocardial infarction or the acute coronary syndrome: meta-analysis with estimates of risk and benefit. Ann Intern Med 2005; 143: 241-250. Go to original source... Go to PubMed...
    9. Gage BF. Can we rely on RE-LY? N Engl J Med 2009; 361: 1200-1202. Go to original source... Go to PubMed...
    10. Connolly SJ, Ezekowitz MD, Yusuf S. Newly identified events in the RE-LY trial. N Engl J Med 2010; 363: 1875-1876. Go to original source... Go to PubMed...
    11. Hohnloser SH, Oldgren J, Yang S. Myocardial ischemic events in patients with atrial fibrillation treated with dabigatran or warfarin in the RE-LY trial. Circulation 2012; 125: 669-676. Go to original source... Go to PubMed...
    12. Uchino K, Hernandez AV. Dabigatran association with higher risk of acute coronary events. Arch Intern Med 2012; 172: 397-402. Go to original source... Go to PubMed...
    13. Mak KH. Coronary and mortality risk of novel oral antithrombotic agents: a meta-analysis of large randomized trials. BMJ Open 2012; 2: e001592. Go to original source... Go to PubMed...
    14. Larsen TB, Rasmussen LH, Skjoth F. Efficacy and safety of dabigatran etexilate and warfarin i, ,real-world" patients with atrial fibrillation: a prospective nationwide cohort study. J Am Coll Cardiol 2013; 61: 2264-2273. Go to original source... Go to PubMed...
    15. Larsen TB, Rasmussen LH, Gorst-Rasmussen A. Myocardial ischemic events in, ,real world" patients with atrial fibrillation treated with dabigatran or warfarin: a nationwide cohort study. Am J Med 2013; Dec 18. pii: S0002-9343(13)01073-5.
    16. Schulman S, Kearon C, Kakkar AK. Extended use of dabigatran, warfarin or placebo in venous thromboembolism. N Engl J Med 2013; 368: 709-718. Go to original source... Go to PubMed...
    17. Mahaffey KW, Stevens SR, White HD. Ischaemic cardiac outcomes in patients with atrial fibrillation treated with vitamin K antagonism or factor Xa inhibition: results from the ROCKET AF trial. Eur Heart J 2014; 35: 233-241. Go to original source... Go to PubMed...
    18. Chatterjee S, Sharma A, Uchino K. Rivaroxaban and risk of myocardial infarction: Insights from a meta-analysis and trial sequential analysis of randomized clinical trials. Cor Art Dis 2013; 24: 628-35. Go to original source... Go to PubMed...
    19. Furugohri T, Sugiyama N, Morishima Y. Antithrombin-independent thrombin inhibitors, but not direct Xa inhibitors, enhance thrombin generation in plasma through inhibition of thrombin-thrombomodulin-protein C systém. Thromb Haemost 2011; 106: 1076-1083. Go to original source... Go to PubMed...
    20. Christersson C, Oldgren J, Wallentin L. Treatment with an oral direct thrombin inhibitor decreases platelet activity but increases markers of inflammation in patients with myocardial infarction. J Intern Med 2011; 270: 215-223. Go to original source... Go to PubMed...
    21. Oldgren J, Wallentin L, Alexander JH. New oral anticoagulants in addition to single or dual antiplatelet therapy after acute coronary syndrome: a systematic review and meta-analysis. Eur Heart J 2013; 34: 1670-1680. Go to original source... Go to PubMed...
    22. Mega JL, Braunwald E, Wiviott SD. Rivaroxaban in patients with a recent acute coronary syndrome. N Engl J Med 2012; 366: 9-19. Go to original source... Go to PubMed...
    23. Oldgren J, Budaj A, Granger CB. Dabigatran vs. placebo in patients with acute coronary syndromes on dual antiplatelet therapy: a randomized, double-blind, phase II trial. Eur Heart J 2011; 32: 2781-2789. Go to original source... Go to PubMed...
    24. Alexander JH, Lopes RD, James S. Apixaban with antiplatelet therapy after acute coronary syndrome. N Engl J Med 2011; 365: 699-708. Go to original source... Go to PubMed...
    25. Heidbuchel H, Verhamme P, Alings M. European Heart Rhythm Association Practical Guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation. Europace 2013; 15: 625-651. Go to original source...

    Return to the content


    Interventional Cardiology

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.